Abstract
Parkinson’s disease (PD) is a complex neurodegenerative disease with both motor and nonmotor symptoms. The major clinical symptoms of PD are due to dopamine deficiency caused by the degeneration of nigrostriatal dopaminergic neurons. As a consequence, current treatments remain focused on the dopamine system. Dopamine-replacement therapy with levodopa has been the mainstay of symptomatic treatment of PD for nearly 40 years. However, levodopa-induced motor complications have led many physicians to advocate alternative options for treatment initiation in suitable patients or as an adjunctive therapy in more advanced cases.
Funding Information
  • GSK, Pfizer, Eli Lilly, Novartis, TEVA, Lundbeck, Bayer Health Care, Solvay, Desitin, Cephalon